Patrick Trojer, Triana Biomedicines CEO
RA, Atlas-backed biotech spins up with $110M in pursuit of protein degradation via molecular glues
RA Capital Management has backed more than just one biotech in the protein degradation space, with the hope of changing the way companies can go …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
